Overview

A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)

Status:
Completed

Trial end date:
2014-08-25

Target enrollment:

Participant gender:

Summary

This is a multi-center, randomized, open-label, phase 1/2 study of continuous weekly paclitaxel and escalating doses of intermittent or continuous OSI-906 in patients with recurrent/relapsed ovarian and other solid tumors.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Astellas Pharma Inc

Treatments:

Albumin-Bound Paclitaxel
Paclitaxel